Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Finished Goods: 2010-2020

Historic Finished Goods for UNITED THERAPEUTICS (UTHR) over the last 9 years, with Mar 2020 value amounting to $43.8 million.

  • UNITED THERAPEUTICS's Finished Goods fell 7.98% to $43.8 million in Q1 2020 from the same period last year, while for Mar 2020 it was $43.8 million, marking a year-over-year decrease of 7.98%. This contributed to the annual value of $43.2 million for FY2019, which is 11.29% down from last year.
  • According to the latest figures from Q1 2020, UNITED THERAPEUTICS's Finished Goods is $43.8 million, which was up 1.39% from $43.2 million recorded in Q4 2019.
  • UNITED THERAPEUTICS's 5-year Finished Goods high stood at $62.2 million for Q3 2017, and its period low was $37.3 million during Q2 2016.
  • Moreover, its 3-year median value for Finished Goods was $48.1 million (2019), whereas its average is $47.5 million.
  • As far as peak fluctuations go, UNITED THERAPEUTICS's Finished Goods surged by 65.15% in 2017, and later fell by 20.58% in 2018.
  • UNITED THERAPEUTICS's Finished Goods (Quarterly) stood at $49.7 million in 2016, then climbed by 12.47% to $55.9 million in 2017, then declined by 12.88% to $48.7 million in 2018, then fell by 11.29% to $43.2 million in 2019, then decreased by 7.98% to $43.8 million in 2020.
  • Its last three reported values are $43.8 million in Q1 2020, $43.2 million for Q4 2019, and $45.0 million during Q3 2019.